In vitro activity of fosfomycin against Escherichia coli isolated from patients with urinary tract infections in Canada as part of the CANWARD surveillance study

Antimicrobial Agents and Chemotherapy

Volumn 58, Issue 2, 2014, Pages 1252-1256

  Karlowsky, James A ^a   Denisuik, Andrew J ^a   Lagacé Wiens, Philippe R S ^a   Adam, Heather J ^a   Baxter, Melanie R ^a   Hoban, Daryl J ^a   Zhanel, George G ^a  

^a UNIVERSITY OF MANITOBA   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

AMOXICILLIN; CIPROFLOXACIN; FOSFOMYCIN; NITROFURANTOIN;

ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; ARTICLE; BACTERIUM ISOLATE; CANADA; DISEASE SURVEILLANCE; ESCHERICHIA COLI; HUMAN; IN VITRO STUDY; MAJOR CLINICAL STUDY; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN; PRIORITY JOURNAL; URINARY TRACT INFECTION;

ANTI-BACTERIAL AGENTS; CANADA; DRUG RESISTANCE, BACTERIAL; EPIDEMIOLOGICAL MONITORING; ESCHERICHIA COLI; ESCHERICHIA COLI INFECTIONS; FOSFOMYCIN; HUMANS; MICROBIAL SENSITIVITY TESTS; URINARY TRACT INFECTIONS;

EID: 84893445483     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.02399-13     Document Type: Article

References (15)

1. Nicolle LE. 2001. Epidemiology of urinary tract infections. Clin. Microbiol. Newsl. 24:135-140. http://www.cmnewsletter.com/issues?issue-key- S0196-4399%2800%29X0302-9.
2. Gupta K, Hooton TM, Naber KG, Wullt B, Colgan R, Miller LG, Moran GJ, Nicolle LE, Raz R, Schaeffer AJ, Soper DE. 2011. International clinical practice guidelines for the treatment of uncomplicated acute cystitis and pyelonephritis in women: a 2010 update by the Infectious Diseases Society of America and the European Society for Microbiology and Infectious Diseases. Clin. Infect. Dis. 52:e103-e120. http://dx.doi.org/10.1093/cid/ciq257.
3. Karlowsky JA, Lagacé-Wiens PR, Simner PJ, DeCorby MR, Adam HJ, Walkty A, Hoban DJ, Zhanel GG. 2011. Antimicrobial resistance in urinary tract pathogens in Canada from 2007 to 2009: CANWARD surveillance study. Antimicrob. Agents Chemother. 55:3169-3175. http://dx.doi.org/10.1128/AAC.00066-11.
4. Sanchez GV, Master RN, Karlowsky JA, Bordon JM. 2012. In vitro antimicrobial resistance of urinary Escherichia coli isolates among U.S. outpatients from 2000 to 2010. Antimicrob. Agents Chemother. 56:2181-2183. http://dx.doi.org/10.1128/AAC.06060-11.
5. Clinical and Laboratory Standards Institute. 2013. Performance standards for antimicrobial susceptibility testing; twenty-third informational supplement. M100-S23. Clinical and Laboratory Standards Institute, Wayne, PA.
6. Zhanel GG, Adam H, Baxter MR, Fuller J, Nichol KA, Denisuik AJ, Lagacé-Wiens P, Walkty A, Karlowsky JA, Schweizer F, Hoban DJ. 2013. Antimicrobial susceptibility of 22746 pathogens from Canadian hospitals: results of theCANWARD2007-2011 study. J. Antimicrob. Chemother. 68(Suppl 1):i7-i22. http://dx.doi.org/10.1093/jac/dkt022.
7. Clinical and Laboratory Standards Institute. 2012. Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically; approved standard-ninth edition. M07-A9. Clinical and Laboratory Standards Institute, Wayne, PA.
8. Karageorgopoulos DE, Wang R, Xu-Hong Y, Falagas ME. 2012. Fosfomycin: evaluation of the published evidence on the emergence of antimicrobial resistance in gram-negative pathogens. J. Antimicrob. Chemother. 67:255-268. http://dx.doi.org/10.1093/jac/dkr466.
9. Ho P-L, Chan J, Lo W-U, Lai EL, Cheung Y-Y, Lau TCK, Chow K-H. 2013. Prevalence and molecular epidemiology of plasmid-mediated fosfomycin resistance genes among blood and urinary Escherichia coli isolates. J. Med. Microbiol. 62:1707-1713. http://dx.doi.org/10.1099/jmm.0.062653-0.
10. Raz R. 2012. Fosfomycin: an old-new antibiotic. Clin. Microbiol. Infect. 18:4-7. http://dx.doi.org/10.1111/j.1469-0691.2011.03636.x.
11. Neuner EA, Sekeres J, Hall GS, van Duin D. 2012. Experience with fosfomycin for treatment of urinary tract infections due to multidrugresistant organisms. Antimicrob. Agents Chemother. 56:5744-5748. http://dx.doi.org/10. 1128/AAC.00402-12.
12. Auer S, Wojna A, Hell M. 2010. Oral treatment options for ambulatory patients with urinary tract infections caused by extended-spectrum-lactamase- producing Escherichia coli. Antimicrob. Agents Chemother. 54: 4006-4008. http://dx.doi.org/10.1128/AAC.01760-09.
13. Liu H-Y, Lin H-C, Lin Y-C, Yu S-H, Wu W-H, Lee Y-J. 2011. Antimicrobial susceptibilities of urinary extended-spectrum beta-lactamaseproducing Escherichia coli and Klebsiella pneumoniae to fosfomycin and nitrofurantoin in a teaching hospital in Taiwan. J. Microbiol. Immunol. Infect. 44:364-368. http://dx.doi.org/10.1016/j.jmii.2010.08.012.
14. Oteo J, Bautista V, Lara N, Cuevas O, Arroya M, Fernández S, Lázaro E, de Abajo FJ, Campos J. 2010. Parallel increase in community use of fosfomycin and resistance to fosfomycin in extended-spectrum-lactamase (ESBL)-producing Escherichia coli. J. Antimicrob. Chemother. 65: 2459-2463. http://dx.doi.org/10.1093/jac/dkq346.
15. Denisuik AJ, Lagacé-Wiens PR, Pitout JD, Mulvey MR, Simner PJ, Tailor F, Karlowsky JA, Hoban DJ, Adam HJ, Zhanel GG. 2013. Molecular epidemiology of extended-spectrum-lactamase-, AmpC-lactamase-, AmpC-lactamase-and carbapenemase-producing Escherichia coli and Klebsiella pneumoniae isolated from Canadian hospitals over a 5 year period: CANWARD 2007-11. J. Antimicrob. Chemother. 68(Suppl 1):i57-i65. http://dx.doi.org/10. 1093/jac/dkt027.